ArticleCurrent oncology (Toronto, Ont.)2022

Advanced Lung Cancer Patients' Use of EGFR Tyrosine Kinase Inhibitors and Overall Survival: Real-World Evidence from Quebec, Canada.

Samia Qureshi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.